Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: endovascular treatment.
- Who it may be relevant to
- Registry conditions: Ischemic Stroke. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion: a Prospective, Registry Study
Overview
Acute ischaemic stroke (AIS) results in high rates of neurological morbidity and mortality, especially in patients with large vessel occlusion (LVO). Endovascular therapy (EVT) has been approved as the most effective treatment for patients with LVO , but about half patients undergoing EVT did not achieve good outcome. The mechanisms of poor prognosis are complex. How to accurately identify serological biomarkers related to patients' clinical prognosis is an important research topic nowadays.
Interventions
- Procedure endovascular treatment
all patients with anterior circulation large vessel occlusion will receive endovascular treatment.
Primary outcome measures
- Dynamic changes in serum biomarkers after endovascular treatment [Time frame: from the baseline to immediately, 30 minutes, 6 hours, and 24 hours after endovascular treatment]
Secondary outcome measures (7)
- favourable functional outcome, defined as modified Rankin Scale (mRS) 0-2 [Time frame: 90±7 days]
- excellent functional outcome, defined as modified Rankin Scale (mRS) 0-1 [Time frame: 90±7 days]
- distribution of modified Rankin Scale (mRS) score [Time frame: 90±7 days]
- early neurological improvement, defined as 4 or more decrease in National Institute of Health stroke scale (NIHSS) [Time frame: 24±8 hours]
- changes in National Institute of Health stroke scale (NIHSS) [Time frame: 24±8 hours]
- symptomatic intracranial hemorrhage (sICH) [Time frame: 24±8 hours]
- occurence of new stroke or other vascular events [Time frame: 90±7 days]
Eligibility criteria
Inclusion criteria
- Age: 18-80 years;
- Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment;
- Pre-stroke mRS: 0-1;
- Baseline NIHSS: ≥6;
- Signed informed consent.
Exclusion criteria
- The presence of contraindications to internal jugular vein cannulation;
- Receiving intravenous thrombolysis;
- Haemorrhagic stroke (cerebral haemorrhage or subarachnoid haemorrhage);
- Coagulation disorders, systemic bleeding tendency, thrombocytopenia (<100×109/L);
- Severe cardiac, hepatic or renal insufficiency (ALT or AST elevated more than 2 times the upper limit of normal value, or serum creatinine elevated more than 1.5 times the upper limit of normal value or in need of dialysis) or other serious medical diseases;
- Severe uncontrolled hypertension (systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 110 mmHg);
- Pregnant or lactating women;
- Other conditions who are not suitable for this trial by investigator.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- General Hospital of Northern Theater Command — Shenyang
Identifiers
NCT: NCT06383182 · Y (2024) 054